Nanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
DALLAS, TX -- Aug. 8, 2024 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations ( ...
Nanoscope Therapeutics to Present at the 2024 American Society of Retina Specialists (ASRS) Annual Scientific Meeting
DALLAS, July 10, 2024 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), ...
Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect
DALLAS, June 18, 2024 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), ...
Nanoscope Therapeutics to Present at the BIO International Convention
DALLAS, May 29, 2024 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), ...
Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality
DALLAS, TX (May 14, 2024) — Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD ...
Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World Congress
DALLAS, May 7, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today announced that its viral ...
Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World Congress
DALLAS, May 7, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today announced that its viral ...
Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting
DALLAS, May 2, 2024 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today announced that its Multi-Characteris ...
Nanoscope Therapeutics to Present at the OIS and Retinal Cell and Gene Therapy Innovation Summits
DALLAS, April 29, 2024 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today announced that Samarendra Mohanty ...
Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical Advisor
DALLAS, April 25, 2024 -- Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, announced today the appointment of Allen C. ...
Nanoscope Therapeutics to Present at the World Orphan Drug Congress 2024
DALLAS, April 17, 2024 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD) ...
Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa
MCO-010 achieved its primary and key secondary endpoints with statistical significance and no serious adverse events Data from the Phase 2b RESTORE trial demonstrate clinically meaningful vision imp ...
Nanoscope Therapeutics Announces Participation in Upcoming Conferences
DALLAS, Feb. 21, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenera ...
Nanoscope to Moderate Discussions at the 4th Annual Gene Therapy Comparability Summit
Dallas, February 14, 2024 — Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, is pleased to announce its role at the 4th An ...
Nanoscope Announces Presentation at the 68th Annual Biophysical Society Meeting
DALLAS, February 12, 2024 — Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that Amir Singh, Ph.D. wil ...
Nanoscope Therapeutics to Present at 47th Annual Macula Society Meeting
Dallas, TX (February 7, 2024) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced that Dr. Victor Gonzalez w ...
Nanoscope Therapeutics Announces Presentation at Bascom Palmer Eye Institute’s 21st Annual Angiogenesis, Exudation, and Degeneration Meeting
DALLAS, February 1, 2024 — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), tod ...
Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa
FDA and EU Regulators provide consistent advice that visual acuity may serve as primary endpoint to evaluate the effectiveness of MCO-010 in the treatment of low-vision retinitis pigmentosa (RP) patie ...
Nanoscope Therapeutics to Present at the 20th Annual Advanced Therapies Week Conference
DALLAS, TX -- Jan. 12, 2024 -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced that Dr. Samarendra Mohant ...
Nanoscope Therapeutics Continues Leadership Growth; Welcomes Accomplished Finance and Biotech Leader Glenn Sblendorio as Chairman of the Board
New Addition Highlights Continued Enhancement of Organization’s Strategic Trajector Dallas, TX – December 4, 2023 – Nanoscope Therapeutics (Nanoscope), a clinical-stage biotechnology company de ...